On the evening of July 24, Jiabeiyou issued a performance forecast stating that first-half 2026 revenue reached 55 million yuan, down 82.07 percent year-on-year. It expects a net loss attributable to shareholders of approximately 100.63 million yuan, a decline of 193.21 percent, and a non-recurring net loss of approximately 99.97 million yuan, down 200.25 percent. The company explained that due to overseas market sentiment and new regulatory requirements, production and sales have not yet fully recovered after adjusting production plans, leading to a sharp swing into the red. Jiabeiyou also disclosed that because its production and operations have been severely impacted and are not expected to return to normal within three months, its shares will be subject to other risk warnings, with the stock abbreviation changed to ST Jiabeiyou, while the daily price limit remains at 20 percent. As of the close on July 24, Jiabeiyou fell 3.02 percent to 9.94 yuan, with a total market capitalization of about 1.67 billion yuan, and its share price has dropped roughly 57 percent this year.
Cabio Biotech Wuhan Co LtdCompany warns of first-half loss exceeding 100 million yuan due to overseas market sentiment and new regulatory requirements, leading to ST designation.